<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharmaceutical Product Guide &#187; testosterone undecanoate injection</title>
	<atom:link href="http://www.pharmaceuticalproductguide.com/blog/tag/testosterone-undecanoate-injection/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.pharmaceuticalproductguide.com/blog</link>
	<description>A comprehensive guide to pharmaceutical products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 09:15:33 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Endo Pharmaceuticals Provides Regulatory Update on AVEED(TM) Injection</title>
		<link>http://www.pharmaceuticalproductguide.com/blog/2009/12/24/endo-pharmaceuticals-provides-regulatory-update-on-aveedtm-injection/</link>
		<comments>http://www.pharmaceuticalproductguide.com/blog/2009/12/24/endo-pharmaceuticals-provides-regulatory-update-on-aveedtm-injection/#comments</comments>
		<pubDate>Thu, 24 Dec 2009 06:36:57 +0000</pubDate>
		<dc:creator>Kimberly O'Brien</dc:creator>
				<category><![CDATA[FDA Approval]]></category>
		<category><![CDATA[Endo Pharmaceuticals]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[new drug application]]></category>
		<category><![CDATA[testosterone undecanoate injection]]></category>

		<guid isPermaLink="false">http://www.pharmaceuticalproductguide.com/blog/?p=180</guid>
		<description><![CDATA[Endo Pharmaceuticals has announced that it received a complete response letter from the FDA regarding the New Drug Application (NDA) for its extended-duration testosterone undecanoate injection, AVEED(TM), for men diagnosed with low testosterone. Low testosterone is also known as hypogonadism. In the complete response letter, the FDA has requested information from Endo to address the [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.pharmaceuticalproductguide.com/blog/wp-content/uploads/2009/12/Endo-Pharmaceuticals.png"><img class="alignright size-full wp-image-181" style="margin: 5px" src="http://www.pharmaceuticalproductguide.com/blog/wp-content/uploads/2009/12/Endo-Pharmaceuticals.png" border="0" alt="Endo Pharmaceuticals" width="200" height="62" /></a>Endo Pharmaceuticals has announced that it received a complete response letter from the FDA regarding the New Drug Application (NDA) for its extended-duration testosterone undecanoate injection, AVEED(TM), for men diagnosed with low testosterone. Low testosterone is also known as hypogonadism. In the complete response letter, the FDA has requested information from Endo to address the agency&#8217;s concerns regarding very rare but serious adverse events, including post-injection anaphylactic reaction and pulmonary oil microembolism.</p>
<p>For the full story, <a href="http://www.pipelinereview.com/index.php/2009120331192/Small-Molecules/Endo-Pharmaceuticals-Provides-Regulatory-Update-on-AVEEDTM-Testosterone-Undecanoate-Injection.html" target="_blank">Click Here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.pharmaceuticalproductguide.com/blog/2009/12/24/endo-pharmaceuticals-provides-regulatory-update-on-aveedtm-injection/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
